Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

The Clinical Menin Inhibitor Ziftomenib and the Nuclear Export Inhibitor Selinexor Synergistically Inhibit the Growth of MLL-r AML

Md. Hafiz Uddin, Amro Aboukameel, Sharif hasan Siddiqui, Husain Khan, Sahar Bannoura, Abhinav Deol, Jay Yang, Gregory Dyson, Asfar Azmi, Lisa Polin, Jaroslaw P. Maciejewski, Suresh Kumar Balasubramanian

Blood (2023) 142 (Supplement 1): 4168.

https://doi.org/10.1182/blood-2023-190638

Published: 2023

Journal Articles

HJKC3-007: Outcomes of Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Asciminib and Other Tyrosine Kinase Inhibitors in Routine Clinical Practice

Blood (2023) 142 (Supplement 1): 7434.

https://doi.org/10.1182/blood-2023-188683

Published: 2023

Journal Articles

Olutasidenib Alone or in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Myelodysplastic Syndromes/Neoplasms (MDS)

Jorge Cortes, Jay Yang, Sangmin Lee, Shira N. Dinner, Eunice S. Wang, Maria R. Baer, William B. Donnellan, Justin M. Watts

Blood (2023) 142 (Supplement 1): 1872.

https://doi.org/10.1182/blood-2023-187404

Published: 2023

Journal Articles

Factors Impacting Response to Olutasidenib in Patients with mIDH1 Acute Myeloid Leukemia

Eunice S. Wang, Brian A. Jonas, Justin M. Watts, Joseph Jurcic, P. Brent Ferrell, Jr., Shira N. Dinner, Jay Yang, Karen Seiter, Alice Mims, William B. Donnellan, William Blum, Jorge Cortes

Blood (2023) 142 (Supplement 1): 6047.

https://doi.org/10.1182/blood-2023-187584

Published: 2023

Journal Articles

Olutasidenib for the Treatment of mIDH1 Acute Myeloid Leukemia in Patients Relapsed or Refractory to Hematopoietic Stem Cell Transplant, Prior mIDH1 Inhibitor, or Venetoclax

Jorge Cortes, Joseph Jurcic, Maria R. Baer, William Blum, P. Brent Ferrell, Jr., Brian A. Jonas, Sangmin Lee, Alice Mims, Shyam Ajay Patel, Gary J. Schiller, Jay Yang, Justin M. Watts

Blood (2023) 142 (Supplement 1): 2888.

https://doi.org/10.1182/blood-2023-187861

Published: 2023

Journal Articles

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice

Blood (2023) 142 (Supplement 1): 7420.

https://doi.org/10.1182/blood-2023-179963

Published: 2023

Journal Articles

A Single Center, 10-Year Experience of CALGB-10403 Regimen in AYA Population with Philadelphia-Chromosome Negative Acute Lymphoblastic Leukemia

Abdul Moiz Khan, Kyle Kondrat, Aditi Sharma, Jay Yang

Blood (2023) 142 (Supplement 1): 5822.

https://doi.org/10.1182/blood-2023-186830

Published: 2023

Journal Articles

Novel Combination of Clinical Menin Inhibitor Ziftomenib and the Nuclear Export Inhibitor Selinexor Synergistically Inhibit MLL-r AML

Md. Hafiz Uddin, Amro Aboukameel, Husain Khan, Sahar Bannoura, Yiwei Li, Abhinav Deol, Jay Yang, Asfar Sohail Azmi, Jaroslaw P. Maciejewski, Suresh Kumar Balasubramanian

Blood (2022) 140 (Supplement 1): 8811–8812.

https://doi.org/10.1182/blood-2022-168151

Published: 2022

Journal Articles

Real-World Outcomes and Cardiac Implications of FLT3 Inhibitors in Acute Myeloid Leukemia

Vikram Dhillon, Abdul Moiz Khan, Ali Al Sbihi, Sushmitha Nanja Reddy, Enxhi Lalo, Harry Ramos, Jay Yang, Anupama Kottam, Suresh Kumar Balasubramanian

Blood (2022) 140 (Supplement 1): 6183–6184.

https://doi.org/10.1182/blood-2022-169932

Published: 2022

Journal Articles

Treatment Free Remission after Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed after a Prior Attempt at TKI Discontinuation-H Jean Khoury Cure CML Consortium Study

Michael Mauro, Alexis Visotcky, Kathryn E Flynn, Jerald P. Radich, Jay Yang, Vivian G. Oehler, Jorge E. Cortes, Vamsi K Kota, Srinivas K. Tantravahi, Arielle Baim, Mei-Jie Zhang, Alexander Hinman, Ehab L. Atallah, Kendra Sweet

Blood (2022) 140 (Supplement 1): 6765–6766.

https://doi.org/10.1182/blood-2022-160138

Published: 2022

Journal Articles

Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study

Ehab L. Atallah, Alexis Visotcky, Kathryn E Flynn, Mei-Jie Zhang, Jerald P. Radich, Jay Yang, Vivian G. Oehler, Srinivas K. Tantravahi, B. Douglas Douglas Smith, Javier Pinilla Ibarz, Kendra Sweet, Michael Mauro, Brian J. Druker, James E. Thompson, Sonia Maldonado-Schmidt, Arielle Baim, Charles A. Schiffer, Vamsi K. Kota, Jorge E. Cortes

Blood (2022) 140 (Supplement 1): 3885–3886.

https://doi.org/10.1182/blood-2022-160172

Published: 2022

Journal Articles

Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia

Blood (2021) 138 (Supplement 1): 2351.

https://doi.org/10.1182/blood-2021-144912

Published: 2021

Journal Articles

A Novel Isoflavone, ME-344, Enhances Venetoclax Antileukemic Activity Against AML Via Suppression of Oxidative Phosphorylation and Purine Biosynthesis

Katie Hege Hurrish, Yongwei Su, Sandra Wiley, Zhanjun Hou, Jenna Carter, Hasini Kalpage, Maik Hüttemann, Holly Edwards, Lisa Polin, Jing Li, Jay Yang, Larry Matherly, Jeffrey W. Taub, Yubin Ge

Blood (2021) 138 (Supplement 1): 2238.

https://doi.org/10.1182/blood-2021-147004

Published: 2021

Journal Articles

Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma

Connie Lee Batlevi, Steven I. Park, Loretta Nastoupil, Tycel Phillips, Jennifer E. Amengual, David Andorsky, Philip Campbell, Pamela McKay, John M. Pagel, John P. Leonard, Jay Yang, Heather O'Connor, Anthony Hamlett, Deyaa Adib, Franck Morschhauser

Blood (2021) 138 (Supplement 1): 2207.

https://doi.org/10.1182/blood-2021-148199

Published: 2021

Journal Articles

A Phase 1/1b Open-Label, Multicenter, Two-Part Study of SETD2 Inhibitor EZM0414 in Patients with Relapsed/Refractory Multiple Myeloma or Diffuse Large B-Cell Lymphoma

Paul G. Richardson, Ruben Niesvizky, Jay Yang, Neelu Yadav, Helen Hsu, Christopher R. Flowers

Blood (2021) 138 (Supplement 1): 1679.

https://doi.org/10.1182/blood-2021-147967

Published: 2021

Journal Articles

Molecular and Genetic Characterization of Tumor Samples from Patients with Relapsed or Refractory Follicular Lymphoma Identifies Factors Influencing Response to Tazemetostat

Sandeep S. Dave, Lanie Happ, Christopher Yasso, Gilles Salles, Connie Lee Batlevi, Tycel Phillips, Jay Yang, Deyaa Adib, Neil R. Michaud, Franck Morschhauser

Blood (2021) 138 (Supplement 1): 1183.

https://doi.org/10.1182/blood-2021-151452

Published: 2021

Journal Articles

Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase 1b Study

Erlene K. Seymour, MD, Yiwei Li, Amro Aboukameel, Radhakrishnan Ramchandren, Golbon Sterbis, Jay Yang, MD, Divaya Bhutani, MD, Ramzi Mohammad, PhD, Asfar Sohail Azmi, PhD, Jeff Zonder, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-140752

Published: 2020

Journal Articles

A Phase 1 Study of Sea-CD70 in Myeloid Malignancies

Ahmed Aribi, MD, Anjali S Advani, MD, William Donnellan, MD, Amir T. Fathi, MD, Marcello Rotta, MD, Benjamin K. Tomlinson, MD, Pankit Vachani, MD, Jay Yang, MD, Phoenix Ho, MD, Guillermo Garcia-Manero, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-136203

Published: 2020

Journal Articles

PTG-300 Eliminates the Need for Therapeutic Phlebotomy in Both Low and High-Risk Polycythemia Vera Patients

Marina Kremyanskaya, Yelena Ginzburg, MD, Andrew T. Kuykendall, MD, Abdulraheem Yacoub, MD, Jay Yang, MD, Suneel K Gupta, PhD, Frank Valone, MD, Sarita Khanna, PhD, Srdan Verstovsek, MD PhD, Ronald Hoffman, MD

Blood (2020) 136 (Supplement 1): 33–35.

https://doi.org/10.1182/blood-2020-137285

Published: 2020

Journal Articles

Tazemetostat Is Associated with Lower Risk for Safety Outcomes Versus the PI3-Kinases Idelalisib, Duvelisib and Copanlisib, in Patients with Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 2 Prior Systemic Treatments: A Matching-Adjusted Indirect Comparison of Single-Arm Trials

David Proudman, MSc,MPH, Dave Nellesen, PhD, Deepshekhar Gupta, MS, Deyaa Adib, MD, Jay Yang, PhD, Michael Keith, PhD PharmD, Khalid Mamlouk, PharmD, BCOP

Blood (2020) 136 (Supplement 1): 16.

https://doi.org/10.1182/blood-2020-137772

Published: 2020

NARROW

The Clinical Menin Inhibitor Ziftomenib and the Nuclear Export Inhibitor Selinexor Synergistically Inhibit the Growth of MLL-r AML

HJKC3-007: Outcomes of Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Asciminib and Other Tyrosine Kinase Inhibitors in Routine Clinical Practice

Olutasidenib Alone or in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Myelodysplastic Syndromes/Neoplasms (MDS)

Factors Impacting Response to Olutasidenib in Patients with mIDH1 Acute Myeloid Leukemia

Olutasidenib for the Treatment of mIDH1 Acute Myeloid Leukemia in Patients Relapsed or Refractory to Hematopoietic Stem Cell Transplant, Prior mIDH1 Inhibitor, or Venetoclax

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice

A Single Center, 10-Year Experience of CALGB-10403 Regimen in AYA Population with Philadelphia-Chromosome Negative Acute Lymphoblastic Leukemia

Novel Combination of Clinical Menin Inhibitor Ziftomenib and the Nuclear Export Inhibitor Selinexor Synergistically Inhibit MLL-r AML

Real-World Outcomes and Cardiac Implications of FLT3 Inhibitors in Acute Myeloid Leukemia

Treatment Free Remission after Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed after a Prior Attempt at TKI Discontinuation-H Jean Khoury Cure CML Consortium Study

Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study

Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia

A Novel Isoflavone, ME-344, Enhances Venetoclax Antileukemic Activity Against AML Via Suppression of Oxidative Phosphorylation and Purine Biosynthesis

Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma

A Phase 1/1b Open-Label, Multicenter, Two-Part Study of SETD2 Inhibitor EZM0414 in Patients with Relapsed/Refractory Multiple Myeloma or Diffuse Large B-Cell Lymphoma

Molecular and Genetic Characterization of Tumor Samples from Patients with Relapsed or Refractory Follicular Lymphoma Identifies Factors Influencing Response to Tazemetostat

Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase 1b Study

A Phase 1 Study of Sea-CD70 in Myeloid Malignancies

PTG-300 Eliminates the Need for Therapeutic Phlebotomy in Both Low and High-Risk Polycythemia Vera Patients

Tazemetostat Is Associated with Lower Risk for Safety Outcomes Versus the PI3-Kinases Idelalisib, Duvelisib and Copanlisib, in Patients with Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 2 Prior Systemic Treatments: A Matching-Adjusted Indirect Comparison of Single-Arm Trials

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only